Unique ID issued by UMIN | UMIN000043283 |
---|---|
Receipt number | R000049414 |
Scientific Title | Questionnaire survey on proper use methods based on experience of using safinamide |
Date of disclosure of the study information | 2021/02/17 |
Last modified on | 2022/07/19 09:50:03 |
Questionnaire survey on proper use methods based on experience of using safinamide
Questionnaire survey on proper use methods of safinamide
Questionnaire survey on proper use methods based on experience of using safinamide
Questionnaire survey on proper use methods of safinamide
Japan |
Parkinson's disease
Neurology |
Others
NO
To summarize the doctor's perspectives for the optimal patient type and optimal usage method when using safinamide for patient with Parkinson's disease and wearing off.
Others
Non-intervention, cross-sectional studies, questionnaire surveys
Others
Not applicable
The following items are evaluated on a four-point scale: 1 (disagree), 2 (somewhat disagree), 3 (somewhat agree), and 4 (agree).
For some questions, the perspective of the subjects will be evaluated by alternative answer or free description.
1) Patietn types in which safinamide should be used from the viewpoints of motor symptoms, motor complications, non-motor symptoms, treatment history, etc. associated with Parkinson's disease
2) Patient types in which safinamide should be withheld, reduced dose or discontinued
3) Use method when dyskinesia appears while using safinamide, optimal safinamide use method for the elderly, and patient types where it is recommended to increase the safinamide dose to a high dose.
4) Demographic profiles of subjects
Observational
30 | years-old | <= |
Not applicable |
Male and Female
Subjects must satisfy all of the follwing criteria.
[Selection criteria in the 1st Questionnaire Survey]
1)Doctors who fully understands the research and have consent to participate in this survey on the website.
2) Doctors over 30 years old
3) Doctors with more than 5 years of experience in treating Parkinson's disease
4) Doctors with 10 or more patients with Parkinson's disease who are continuously treated
5) Doctors with one or more patients who have prescribed safinamide
[Selection criteria in the 2nd Questionnaire Survey]
1) Doctors who fully understands the research and have consent to participate in this survey on the website.
2) Doctors over 30 years old
3) Doctors with more than 5 years of experience in treating Parkinson's disease
4) Doctors with 10 or more patients with Parkinson's disease who are continuously treated
5) Doctors who have prescribed safinamide for 5 or more patients and have been using it for 3 months or more
[Exclusion criteria in the 1st Questionnaire Survey]
1) Doctors who cannot fill out and answer questionnaires by themselves
2) Doctors who did not complete the answers to all the questionnaires
[Exclusion criteria in the 2nd Questionnaire Survey]
1) Doctors who cannot fill out and answer questionnaires by themselves
2) Doctors who did not complete the answers to all the questionnaires
3) Doctors who are judged by the principal investigator / coordinator to be inappropriate for the results of this study
150
1st name | Atsushi |
Middle name | |
Last name | Takeda |
National hospital organization sendai nishitaga national hospital
Department of Neurology
982-8555
2-11-11 Kagitorihoncho, Taihaku-ku, Sendai, 982-8555
022-245-2111
takeda.atsushi.nc@mail.hosp.go.jp
1st name | Takayuki |
Middle name | |
Last name | Ishida |
Eisai Co., Ltd.
Medical HQs
162-0812
Sumitomo Fudosan Iidabashi building No.3, Nishigoken-cho 13-1, Shinjuku-ku, Tokyo
03-5228-7112
t8-ishida@hhc.eisai.co.jp
National hospital organization sendai nishitaga national hospital,
Eisai Co., Ltd.
Eisai Co., Ltd.
Profit organization
Japan
Takahashi Clinic Ethics Committee
5-1-31 , Iwayakita-machi ,Nada-ku, Kobe City, Hyogo,
078-882-6432
kishimoto.satoshi@neues.co.jp
NO
株式会社QLife
2021 | Year | 02 | Month | 17 | Day |
https://doi.org/10.1155/2022/3203212
Published
https://doi.org/10.1155/2022/3203212
150
As published in the paper.
2022 | Year | 07 | Month | 19 | Day |
As published in the paper.
As published in the paper.
As published in the paper.
As published in the paper.
Completed
2021 | Year | 02 | Month | 07 | Day |
2021 | Year | 02 | Month | 16 | Day |
2021 | Year | 02 | Month | 22 | Day |
2021 | Year | 06 | Month | 10 | Day |
2021 | Year | 08 | Month | 10 | Day |
2021 | Year | 08 | Month | 10 | Day |
2021 | Year | 08 | Month | 10 | Day |
This study was conducted as a questionnaire survey on the doctor panel of M3 Co., Ltd. via the web. The collected answers to the questionnaire will be anonymized and individuals will not be identified.
2021 | Year | 02 | Month | 09 | Day |
2022 | Year | 07 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049414
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |